← Research library

Registered Dalargin and Leitragin COVID-19 trial

Completed trial · registry only · 2020

Registered population or design
320 actual enrollees reported. The four arm descriptions list 80 participants apiece.
Results availability
The registry lists a completed 320-person Phase III trial with standard care, Dalargin, Leitragin and combination arms. No results are posted in the registry.

Reported findings and study design

The patent gives no measured outcomes

Open-label randomized parallel-group study. The registry provides actual overall enrollment and describes four planned groups.

Dose, route and schedule

All four arms received the study’s background care. The add-on arms specify Dalargin 1 mg intramuscularly daily for 10 days, Leitragin 10 mg by inhalation daily until pulmonary complications resolved, or both.

Protocol source ↗ · ClinicalTrials.gov record and sponsor-submitted enrollment and intervention fields.

Results · ClinicalTrials.gov record and sponsor-submitted enrollment and intervention fields.
MeasureResultComparison, timing and statistics
Actual enrollment320 participants
Arm descriptions as specified by the sponsor
Arm descriptions as specified by the sponsor
ArmListed group sizeStudy intervention alongside background care
Comparison80Background care only
Dalargin801 mg IM daily for 10 days
Leitragin8010 mg inhaled daily until pulmonary complications resolved
Combination80Dalargin plus Leitragin on the same schedules

Arm sizes in the protocol descriptions. Arm-level enrollment and outcomes are unavailable.

Source for these results ↗ · Reviewed 2026-11-15

Study limitations and source details

Study limitations

  • Intervention labels and dose descriptions conflict in the registry. The arm summaries follow the detailed descriptions. The listed treatment reflects 2020 study methods.

Source details

Trial registry

ClinicalTrials.gov record and sponsor-submitted enrollment and intervention fields.

Sources checked

Citation

Trial protocol / registrationFull text available

Burnasyan Federal Medical Biophysical Center. Registered Dalargin and Leitragin COVID-19 trial ClinicalTrials.gov NCT04346693.

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards